Merck & Co. failed to convince the FDA to permit the firm to market its cholesterol-lowering medications Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) as therapies to reduce the risk of cardiovascular (CV) events – CV death, nonfatal heart attacks and strokes, hospitalization for unstable angina or the need for revascularization – in patients with coronary heart disease.
Merck Fails To Win Zetia/Vytorin CV Risk Reduction Claim
Merck & Co. failed to convince the FDA to permit the firm to market its cholesterol-lowering medications Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) as therapies to reduce the risk of cardiovascular (CV) events – CV death, nonfatal heart attacks and strokes, hospitalization for unstable angina or the need for revascularization – in patients with coronary heart disease.
More from Cardiovascular
• By
Chief medical officer Eliav Barr, responsible for overseeing clinical development, talked to Scrip in an interview at Merck’s headquarters about the company’s pipeline diversification.
• By
Over the past few months, Chinese developers of CNS and cardiometabolic therapies have attracted the interest of domestic investors, amid generally modest funding activity.
• By
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
• By
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
More from Therapy Areas
• By
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
• By
The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.